Back to contents

CCR5 inhibitors

Maraviroc

Names: Maraviroc, MVC, Celsentri

Approved dosage: The dose of maraviroc is dependent on the other anti-HIV drugs you take. Your HIV doctor or pharmacist will talk to you about which dose is appropriate for you. Most people will take one blue tablet (300mg or 150mg) twice daily.

Note: Maraviroc should only be used by people with a type of HIV called ‘CCR5-tropic’ HIV. Not everybody has this type of virus; if you do not have it, you should not take maraviroc. Your HIV clinic should carry out a test called a tropism test to see if you have CCR5-tropic HIV before prescribing the drug.

Tips on taking it: Take the dose with or without food.

Common side-effects: Postural hypotension (dizziness on standing too quickly), anaemia, nausea, diarrhoea, abdominal pain, bloating, loss of appetite, flatulence, weakness, depression, difficulty in sleeping, raised liver enzyme levels, rash. 

Rare side-effects: Liver problems, allergic (hypersensitivity) reaction including itchy rash, yellowing of the eyes, vomiting, dark urine and abdominal pain on the right side.

Resistance: Resistance to maraviroc is still being studied and appears to occur in a different way to other anti-HIV drugs.

Children: Celsentri can be used by children of 2 years and over. Oral solution available.

Key drug interactions: Dose adjustment needed when maraviroc is taken with some other anti-HIV drugs.

If you are prescribed certain drugs, including oral ketoconazole (not the shampoo), itraconazole and clarithromycin, your dose of maraviroc may need to be changed. Your doctor or pharmacist will discuss this with you.

People on the anti-TB drug rifampicin and on carbamazepine, phenobarbital and phenytoin (used to treat epilepsy) will need an adjusted dose of maraviroc. Your doctor or pharmacist will discuss this with you.

St John’s wort should not be taken with maraviroc.

Anti-HIV drugs

Published June 2018

Last reviewed June 2018

Next review June 2021

Contact NAM to find out more about the scientific research and information used to produce this booklet.

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.